Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $215.7 million.

  • Apellis Pharmaceuticals' Net Income towards Common Stockholders rose 47546.34% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 11798.04%. This contributed to the annual value of -$197.9 million for FY2024, which is 6256.76% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Net Income towards Common Stockholders is $215.7 million, which was up 47546.34% from -$42.2 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Income towards Common Stockholders peaked at $215.7 million during Q3 2025, and registered a low of -$219.2 million during Q2 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$138.9 million (2022), whereas its average is -$107.6 million.
  • In the last 5 years, Apellis Pharmaceuticals' Net Income towards Common Stockholders plummeted by 22255.85% in 2021 and then soared by 47546.34% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Net Income towards Common Stockholders stood at -$147.9 million in 2021, then dropped by 12.21% to -$166.0 million in 2022, then skyrocketed by 46.64% to -$88.6 million in 2023, then soared by 58.99% to -$36.3 million in 2024, then skyrocketed by 693.78% to $215.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at $215.7 million for Q3 2025, versus -$42.2 million for Q2 2025 and -$92.2 million for Q1 2025.